NCQA offers PCMH certification track

Luke Gale | | Health Exec | Policy & Regulations

Healthcare consultants now have a way to demonstrate their expertise in the area of patient-centered medical homes (PCMH). The National Committee for Quality Assurance (NCQA) established the PCMH content expert certification to help provider organizations gauge consultants’ knowledge of the NCQA PCMH recognition program.

With 5,000 currently recognized, NCQA’s PCMH program has been the most widely adopted, according to a Jan. 17 statement. Consultants can build and prove their knowledge of NCQA’s specific PCMH requirements through the certification program, which requires arrending two educational seminars and passing an exam on topics from application procedures to documentation requirements. 

More information on the certification program is available on the NCQA website. 

Luke Gale

Related Content

Q&A: Proposed changes to Social Security Act would recognize pharmacists as healthcare providers
10 signs AI is ‘eating the world (of venture capital)’
Mangione now faces federal charges, death penalty in murder of UHC CEO
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.